Zydus Lifesciences gets USFDA’s EIR, nod for oncology injectable facility in Ahmedabad
The inspection was conducted from November 04, 2025 to November 13, 2025
Zydus Lifesciences has received the Establishment Inspection Report (EIR) and approval letter from the USFDA for the Pre-Approval Inspection (PAI) conducted at SEZ oncology injectable manufacturing site in SEZ1, Ahmedabad, in relation to the new isolator injectable line. The inspection was conducted from November 04, 2025 to November 13, 2025.
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
